Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 79Cyclophosphamide 57Specimen Handling 53Carboplatin 50fludarabine 46Nivolumab 42Magnetic Resonance Spectroscopy 42Gemcitabine 38Biopsy 37Bevacizumab 34Dexamethasone 31Paclitaxel 28venetoclax 27Docetaxel 27Cisplatin 26Injections 25atezolizumab 24Pemetrexed 23Ipilimumab 22Capecitabine 22Temozolomide 20Oxaliplatin 19abemaciclib 18Rituximab 18Lenalidomide 18Fulvestrant 18Cetuximab 18Azacitidine 17Fluorouracil 16Vincristine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Biopsy, Large-Core Needle × 90 days × Clear all
NCT05053971 2026-04-13

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡